Puma Biotechnology Announces Resignation of Steven Lo as Chief Commercial Officer, Effective October 18, 2019
October 08, 2019 at 09:17 am EDT
Share
On October 4, 2019, Steven Lo notified Puma Biotechnology, Inc. of his decision to resign as the Company's Chief Commercial Officer, effective October 18, 2019. Mr. Lo has informed the Company that he has accepted a position as the Chief Executive Officer of a company that is preparing for commercialization and focusing on the development of therapies for the central nervous system. Mr. Lo's responsibilities will be assumed by the Company's existing commercial team while the Company initiates a search for a replacement.
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
PUMA BIOTECHNOLOGY, INC. 
